SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

Search

Pharma Mar SA

Uždarymo kaina

84.6 -7.74

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

83

Max

85.05

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-13M

-3.9M

Pardavimai

-9.5M

39M

P/E

Sektoriaus vid.

78.186

51.198

Pelnas, tenkantis vienai akcijai

-0.22

Dividendų pajamingumas

0.91

Pelno marža

-10.047

Darbuotojai

500

EBITDA

-16M

-1.1M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+18.61% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.91%

2.40%

Kitas uždarbis

2025-07-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

141M

1.5B

Ankstesnė atidarymo kaina

92.34

Ankstesnė uždarymo kaina

84.6

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Pharma Mar SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-06 14:31; UTC

Uždarbis

New York State Retirement Fund Posts 5.84% Annual Investment Return

2025-06-06 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-06 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-06 20:33; UTC

Uždarbis

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025-06-06 19:36; UTC

Rinkos pokalbiai

Oil Futures Post Solid Weekly Gains -- Market Talk

2025-06-06 19:28; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

2025-06-06 18:46; UTC

Rinkos pokalbiai

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

2025-06-06 18:02; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Continues to Decline -- Market Talk

2025-06-06 16:35; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025-06-06 16:34; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025-06-06 16:21; UTC

Rinkos pokalbiai

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

2025-06-06 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-06 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-06 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-06-06 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-06-06 16:07; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-06-06 16:07; UTC

Rinkos pokalbiai

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

2025-06-06 15:53; UTC

Rinkos pokalbiai

Mexican Inflation Seen Rising in May -- Market Talk

2025-06-06 15:36; UTC

Rinkos pokalbiai

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

2025-06-06 15:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-06 15:33; UTC

Rinkos pokalbiai

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

2025-06-06 15:16; UTC

Rinkos pokalbiai

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

2025-06-06 15:05; UTC

Rinkos pokalbiai

Silver at its Highest In Nearly 15 Years -- Market Talk

2025-06-06 14:35; UTC

Rinkos pokalbiai

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

2025-06-06 14:28; UTC

Rinkos pokalbiai

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

2025-06-06 14:28; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-06 14:28; UTC

Rinkos pokalbiai

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

2025-06-06 14:15; UTC

Rinkos pokalbiai

Oil Rises on U.S.-China Talks Optimism -- Market Talk

2025-06-06 14:12; UTC

Uždarbis

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

2025-06-06 14:09; UTC

Uždarbis

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Pharma Mar SA Prognozė

Kainos tikslas

By TipRanks

18.61% į viršų

12 mėnesių prognozė

Vidutinis 108.999 EUR  18.61%

Aukščiausias 110 EUR

Žemiausias 108 EUR

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pharma Mar SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

72.75 / 74.3Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.